Quartel Adrian W's Form 4 filing
Zevra Therapeutics, Inc. (ZVRA) · filed Feb 2, 2026
- Accession no.
- 0001910132-26-000002
- Filed
- Feb 2, 2026
- Trade date
- Jan 29-30, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 3 derivative transactions. Open-market sales total $40.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Quartel Adrian WCIK 0001910132 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | Common Stock | MOption exerciseAcquired | +11,333 | – | – | 14,256 | Direct | |
| Jan 30, 2026 | Common Stock | SSaleDisposed | −4,533 | $8.83 | −$40,026.39 | 9,723 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 29, 2026 | Common Stock | AGrant or awardAcquired | +37,500 | $0.00 | $0 | 37,500 | Direct | |
| Jan 29, 2026 | Common Stock | AGrant or awardAcquired | +75,000 | $0.00 | $0 | 75,000 | Direct | |
| Jan 30, 2026 | Common Stock | MOption exerciseDisposed | −11,333 | $0.00 | $0 | 22,667 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.